SAN DIEGO—Resmed, a health technology company focused on sleep, breathing and care delivered in the home, announced it has completed its acquisition of Noctrix Health, Inc., a medical device company developing clinically validated wearable therapeutics for chronic neurological disorders.
The company said the acquisition expands Resmed’s clinical sleep health portfolio into an area of what Resmed said it a significant unmet need—the treatment of restless legs syndrome (RLS), the third most prevalent sleep disorder. Noctrix Health said joining Resmed brings an opportunity to expand patient access and accelerate impact for providers, patients and health systems.
Noctrix’s Nidra Tonic Motor Activation (TOMAC) Therapy is an FDA De Novo classified, noninvasive, nonpharmacologic treatment designed to reduce symptoms of moderate-to-severe RLS and improve sleep quality in adults who have not found sufficient relief with drug therapy.
“Our acquisition of Noctrix Health marks an important step forward in advancing our 2030 strategy and expanding our clinical sleep health portfolio,” said Mick Farrell, chairman and CEO of Resmed. “We are excited to welcome the Noctrix team to Resmed and scale solutions that improve lives through better sleep and home health technologies.”
Resmed said it plans to integrate Noctrix’s technology into its portfolio of connected devices and digital health solutions.
“Since founding Noctrix, our mission has been to deliver innovative, nonpharmacologic solutions for people living with RLS who have limited treatment options,” said Shri Raghunathan, president and CEO of Noctrix Health. “Joining Resmed will help us advance that mission, enabling us to expand access to TOMAC therapy and reach more patients with a clinically validated solution that can help meaningfully improve sleep and quality of life.”
Resmed’s acquisition of Noctrix Health, Inc. was previously announced on April 30, 2026, during Resmed’s Q3 FY26 earnings call. Upon completion of the acquisition today, Noctrix became a wholly owned subsidiary within the Resmed group.